The text starts here.

Products

Our Products (Major Products Worldwide)

At Eisai, we are currently undergoing a transformation from a two brand structure built upon the anti-Alzheimer's agent Aricept® and the proton-pump inhibitor Pariet®/AcipHex® to a multi-brand structure established for the coordinated global launches for each of the six products of Halaven®, Fycompa®, BELVIQ®, Humira®, Lyrica® and Lunesta®, which form the basis of our next-generation product portfolio.

Oncology is one of the important therapeutic areas in which we concentrate our efforts. In addition to Halaven®, a novel anticancer agent discovered and developed in-house, we currently market antiemetic agent Aloxi® and injectable anticlotting agent Fragmin® in the United States and anticancer agent Symbenda®/Treakisym® as a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer in Singapore, South Korea and Japan.

We also continue to define diseases of the central nervous system and epilepsy as key franchise areas in neurology. Aricept was first launched in January 1997 in the United States and is now approved and marketed in more than 90 countries worldwide. Moreover, as a leading pharmaceutical company in the development of anti-Alzheimer's treatments, we are expanding our educational activities that promote the early diagnosis and early treatment of Alzheimer's disease. In epilepsy, a relatively new area of therapeutic focus at Eisai, we provide multiple treatment options to cater to a diverse range of patient needs. These include Fycompa®, an AMPA receptor antagonist discovered in-house, Inovelon®/BANZEL®, a treatment for the rare disease of Lennox-Gastaut syndrome, and Zonegran® and Zebinix® as treatments for partial-onset seizures.

Another innovative neurology product we provide is BELVIQ®, which was launched in the United States in June 2013 as a treatment for obesity in adults. Furthermore, we have expanded the licensing agreement to market and distribute BELVIQ® in 21 countries throughout the Americas, to also include most countries and territories worldwide, most notably the European Union, Japan and China.

Meanwhile, as an advancement in the field of biologics represented by therapeutic antibodies, based on a licensing agreement with AbbVie GK, Eisai has launched Humira®, a fully human anti-TNF-α monoclonal antibody, as a treatment for immune-mediated diseases in Japan, South Korea and Taiwan. And in addition, in Japan we are focusing our efforts on promoting Lyrica®, a treatment for postherpetic neuralgia and Lunesta®, a treatment for insomnia.

(Information current as of June 2014)

Major Products

  Sales Regions
Oncology-Related Products
  Aloxi (antiemetic agent)
  Halaven (anticancer agent)
  Fragmin (injectable anticlotting agent)
 
Americas
Japan, US, EUR, Asia
US
Aricept (anti-Alzheimer's agent) Japan, US, EUR, Asia
Pariet/AcipHex (proton-pump inhibitor) Japan, US, EUR, Asia
Humira (fully human anti-TNF-α monoclonal antibody) Japan, South Korea, Taiwan
Epilepsy Products
  Inovelon/BANZEL (Lennox-Gastaut syndrome treatment)
  Zonegran (antiepileptic agent)
  Zebinix (antiepileptic agent)
  Fycompa (antiepileptic agent)
 
Americas, EUR, Asia
Americas, EUR, Asia
EUR
Americas, EUR, Asia

(Information current as of June 2014)

Major Products by Region

Japan Prescription Pharmaceuticals
Aricept (anti-Alzheimer's agent)
Pariet (proton-pump inhibitor)
Halaven (anticancer agent)
Humira (fully human anti-TNF-α monoclonal antibody)
Methycobal (peripheral neuropathy treatment)
Lyrica (postherpetic neuralgia treatment)
Warfarin (oral anticoagulant)
Actonel (osteoporosis treatment)
Selbex (gastritis / gastric ulcer treatment)
Lunesta (insomnia treatment)
Consumer Healthcare (Over-the-Counter) Products
Chocola BB group (including Vitamin B2 preparation Chocola BB Plus)
Americas Halaven (anticancer agent)
Fycompa (antiepileptic agent)
BELVIQ (antiobesity agent)
Aloxi (antiemetic agent)
AcipHex (proton-pump inhibitor)
BANZEL (antiepileptic agent)
Fragmin (injectable anticlotting agent)
Aricept (anti-Alzheimer's agent)
Europe Halaven (anticancer agent)
Fycompa (antiepileptic agent)
Zonegran (antiepileptic agent)
Zebinix (antiepileptic agent)
Inovelon (Lennox-Gastaut syndrome treatment)
Aricept (anti-Alzheimer's agent)
Pariet (proton-pump inhibitor)
Asia Halaven (anticancer agent)
Humira (fully human anti-TNF-α monoclonal antibody)
Methycobal (peripheral neuropathy treatment)
Aricept (anti-Alzheimer's agent)
Pariet (proton-pump inhibitor)
Stronger Neo-Minophagen C / Glycyron tablets (liver disease / allergic disease treatment)

(Information current as of June 2014)

Related Links